Adagio Therapeutics (ADGI) Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. FDX
4. ABBV
5. META
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Adagio Therapeutics (ADGI) Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

Adagio Therapeutics (ADGI) Shares Are Up 80% Since Friday. Here's Why

November 29, 2021 7:38 AM EST

Shares of Adagio Therapeutics (NASDAQ: ADGI) are up over 33% in pre-open Monday after the company provided additional information related to its flagship SARS-CoV-2 antibody, ADG20, to address the new COVID variant Omicron.

Adagio shares closed 34.12% higher on Friday on growing concerns related to a new variant. This morning, the company issued an update on its ADF20 cocktail.

Due to the highly conserved and immunorecessive nature of the... More